<DOC>
	<DOCNO>NCT00694109</DOCNO>
	<brief_summary>To evaluate safety efficacy extend dose mipomersen ( ISIS 301012 ) participant familial hypercholesterolemia severe hypercholesterolemia lipid-lowering therapy complete either 301012-CS5 ( NCT00607373 ) , 301012-CS7 ( NCT00706849 ) , 301012-CS17 ( NCT00477594 ) MIPO3500108 ( NCT00794664 ) clinical drug trial .</brief_summary>
	<brief_title>An Open-label Extension Study Assess Long-term Safety Efficacy ISIS 301012 ( Mipomersen ) Patients With Familial Hypercholesterolemia Severe-Hypercholesterolemia</brief_title>
	<detailed_description>All familial hypercholesterolemia ( FH ) severe hypercholesterolemia participant tolerate treatment regimen Protocol 301012-CS5 ( NCT00607373 ) , 301012-CS7 ( NCT00706849 ) MIPO3500108 ( NCT00794664 ) satisfactorily complete study Week 28 eligible participation open label treatment extension study 4 year mipomersen commercially available , whichever come first . Consenting participant tolerate mipomersen satisfactorily complete 301012-CS17 ( NCT00477594 ) Year 3 may also enroll additional 2 year treatment study mipomersen commercially available , whichever come first . All participant , enter study , receive 200 mg mipomersen ( ISIS 301012 ) subcutaneously ( s.c. ) every week , include randomize placebo initial study . Participants originally enrol Protocol 301012-CS5 ( NCT00607373 ) weigh &lt; 50 kg receive 160 mg every week . Dose adjustment ( 70 mg injection administer three time per week , separate day ) allow participant tolerate previous issue tolerate week injection due injection site reaction ( ISRs ) flu-like symptom . Study visit clinical lab assessment include hematology differential , chemistry , serum lipid panel ( total cholesterol , LDL-C , low density lipoprotein cholesterol ( VLDL-C ) , high density lipoprotein cholesterol ( HDL-C ) , apolipoprotein B ( apoB ) , apoA-1 , triglyceride ( TG ) Lp ( ) , urinalysis perform every 4-10 week treatment period . Plasma trough mipomersen ( ISIS 301012 ) level measure estimate exposure . Participants complete dose discontinue prematurely study reason follow safety 24 week ( safety follow-up period ) last dose mipomersen ( ISIS 301012 ) long case significant adverse event ( AE ) abnormal biochemical clinical finding . Participants require return study center clinical evaluation clinical laboratory test every 8 week safety follow-up period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<mesh_term>Infant , Newborn , Diseases</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>Satisfactory completion dose initial study ( Protocol 301012CS5 [ NCT00607373 ] , 301012CS7 [ NCT00706849 ] , 301012CS17 [ NCT00477594 ] , MIPO3500108 [ NCT00794664 ] ) Had new condition worsen exist condition opinion Investigator would make participant unsuitable enrollment , could interfere participant participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Familial Hypercholesterolemia</keyword>
	<keyword>FH</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>HeFH</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>HoFH</keyword>
</DOC>